Parkinson’s Disease: Available Clinical and Promising Omics Tests for Diagnostics, Disease Risk Assessment, and Pharmacotherapy Personalization

Trifonova O.P., Maslov D.L., Balashova E.E., Urazgildeeva G.R., Abaimov D.A., Fedotova E.Yu, Poleschuk V.V., Illarioshkin S.N., Lokhov P.G.
DIAGNOSTICS. — 2020. — Vol. 10, no. 5. 
Аннотация: Parkinson’s disease is the second most frequent neurodegenerative disease, representing asignificant medical and socio-economic problem. Modern medicine still has no answer to the questionof why Parkinson’s disease develops and whether it is possible to develop an effective system ofprevention. Therefore, active work is currently underway to find ways to assess the risks of thedisease, as well as a means to extend the life of patients and improve its quality. Modern studiesaim to create a method of assessing the risk of occurrence of Parkinson’s disease (PD), to searchfor the specific ways of correction of biochemical disorders occurring in the prodromal stage ofParkinson’s disease, and to personalize approaches to antiparkinsonian pharmacotherapy. In thisreview, we summarized all available clinically approved tests and techniques for PD diagnostics.Then, we reviewed major improvements and recent advancements in genomics, transcriptomics,and proteomics studies and application of metabolomics in PD research, and discussed the majormetabolomics findings for diagnostics and therapy of the disease.

Полный текст...